Contineum Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Contineum Therapeutics, Inc. (CTNM) reported Diluted Shares Outstanding (Weighted Average) of 37.47 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-07-30
- Contineum Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 37.47M shares, a 44.69% increase year-over-year.
- Contineum Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 37.34M shares, a 44.34% increase year-over-year.
- Contineum Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-06-30 was 25.90M shares, a 10.88% increase year-over-year.
- Contineum Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-03-31 was 25.87M shares, a 991.95% increase year-over-year.
- Contineum Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 27.70M shares, a 43.14% increase from fiscal 2024.
- Contineum Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 19.35M shares, a 469.95% increase from fiscal 2023.
- Contineum Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 3.40M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 37.47M shares 10-Q · filed 2026-07-30 | 37.40M shares 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | 37.34M shares 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 27.70M shares 10-K · filed 2026-03-05 | |||
| 2025-06-30 | 25.90M shares 10-Q · filed 2026-07-30 | 25.88M shares 10-Q · filed 2026-07-30 | 25.88M shares derived: average of 3 quarters · filed 2026-07-30 | 25.84M shares derived: average of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | 25.87M shares 10-Q · filed 2026-05-05 | 25.87M shares derived: average of 2 quarters · filed 2026-05-05 | 25.82M shares derived: average of 3 quarters · filed 2026-05-05 | 25.20M shares derived: average of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | 25.86M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 25.80M shares derived: average of 2 quarters · filed 2026-03-05 | 24.98M shares derived: average of 3 quarters · filed 2026-03-05 | 19.35M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 25.73M shares 10-Q · filed 2024-11-06 | 24.54M shares derived: average of 2 quarters · filed 2024-11-06 | 17.18M shares 10-Q · filed 2024-11-06 | 13.67M shares derived: average of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | 23.36M shares 10-Q · filed 2024-08-14 | 12.86M shares 10-Q · filed 2024-08-14 | 9.66M shares derived: average of 3 quarters · filed 2025-03-06 | 7.82M shares derived: average of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | 2.37M shares 10-Q · filed 2024-05-16 | 2.81M shares derived: average of 2 quarters · filed 2025-03-06 | 2.65M shares derived: average of 3 quarters · filed 2025-03-06 | 2.86M shares derived: average of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | 3.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 2.78M shares derived: average of 2 quarters · filed 2025-03-06 | 3.03M shares derived: average of 3 quarters · filed 2025-03-06 | 3.40M shares 10-K · filed 2025-03-06 |
| 2023-09-30 | 2.32M shares 10-Q · filed 2024-11-06 | 2.92M shares derived: average of 2 quarters · filed 2024-11-06 | 3.45M shares 10-Q · filed 2024-11-06 | |
| 2023-06-30 | 3.51M shares 10-Q · filed 2024-08-14 | 3.51M shares 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 2.28M shares 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |